With great interest, we read the work of Adjedj and colleagues (1), demonstrating the dose-response curve of intracoronary adenosine for hyperemia, expressed in terms of coronary flow velocity. The authors should be congratulated for this elegant study, which by focusing on the flow response to adenosine has important incremental value over previous studies on the subject. Nonetheless, some considerations may require further attention.
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First, the authors studied unobstructed coronary vessels only. Although, as explained by the authors, only in these vessels an adequate dose-response curve of adenosine for flow velocity can be obtained, it is important to realize that vasoreactivity in the distal microvasculature is altered in the presence of epicardial stenosis due to altered tone regulation and remodeling of the microcirculation (2). Hence, the present findings apply to unobstructed coronary vessels and cannot be unequivocally extrapolated to stenosed vessels. Nonetheless, the extrapolation to the fractional flow reserve (FFR) framework is hypothesis-generating. Because the expected difference between the minimal and observed FFR is smaller than the variability of the FFR measurement itself for adenosine doses above 40 mg, the authors document that low-dose adenosine administration does not lead to relevant ambiguities in FFR assessment. This finding importantly strengthens the conclusions derived from clinical studies that were previously scrutinized for using low(er)-dose adenosine administration (3,4).
Second, in contrast to many interventional practices, the authors decided not to flush the dead space after administration of adenosine, and estimate a 15% difference in administered adenosine versus the actual dose reaching the coronary ostium. However, a 6-F guiding catheter as used by the authors has over 2 ml worth of dead space. With administration of the documented dose of adenosine in 8 ml (1), a 2-ml dead space means 25% of the administered dose will not reach the coronary ostium: of the proposed 160-to 200-mg and 60-to 100-mg doses for the left coronary artery and right coronary artery, respectively, only 120 to 150 mg and 45 to 75 mg reached the coronary ostium.
This does not invalidate the study results, but stresses the notably low doses of intracoronary adenosine required to exhaust adenosine-dependent vasodilation, and suggests that the proposed doses should not be firmly extrapolated to the clinical setting.
Finally, it is important to realize that neither this study, nor most of the preceding studies using FFR as the endpoint, assess the achievement of maximal hyperemia. Despite using this terminology, all of these studies merely investigate the amount of adenosine required to exhaust adenosine-dependent vasodilation. It is well-known that many vasoconstrictors interfere with the complete abolishment of vasomotor tone required to achieve "maximal" This is axiomatic in light of the environment in
